Outcome Measure	Evidence	Implications
Disease-oriented evidence
Efficacy on management of chemotherapy-induced nausea	Clear	Proved by RCT and observational studies
Efficacy on management of chemotherapy-induced vomiting	Clear	Proved by RCT and observational studies
Cardiac safety	Clear	Proved by RCT studies
Patient-oriented evidence
Improvement in quality of life	Clear	Proved by RCT and observational studies
High adherence to guidelines	Clear	One shot administration provides a complete adherence to guidelines for most HEC and MEC regimens
Sparing of corticosteroids	Moderate	Observed in clinical practice. Trials are currently underway
Economic evidence
Cost effectiveness	Moderate	A cost-effectiveness analysis suggests that NEPA, providing a superior CINV prevention, lowers total medical costs due to CINV-related adverse events compared to other antiemetic regimens.

Abbreviations: RCT, randomized controlled trial; HEC, highly emetogenic chemotherapy; MEC, moderate emetogenic chemotherapy; CINV, chemotherapy-induced nausea and vomiting.